依达拉奉治疗不影响不同尿酸水平急性缺血性卒中患者的预后

目的:探讨依达拉奉治疗急性缺血性卒中患者尿酸水平与90d时临床结局的关系。方法:回顾性研究发病24h内入院的且改良Rankin量表(ModifiedRankinScale,MRS)评分<2的缺血性卒中患者。以尿酸水平中位数值(333μmol/L)作为临界值将患者分为低尿酸(≤333μmol/L)组和高尿酸(>333μmol/L)组,并比较了90d时两组患者的临床资料及良好预后(MRS<2)的关系。进一步研究使用及未使用依达拉奉的尿酸水平与90d时结局指标之间的关系。结果:高尿酸组男性、高血压、心房颤动和心源性卒中的比例高于低尿酸组。高尿酸组90d时MRS<2的患者比例也较高(P=0.013);但在多因素分析中,尿酸与良好结局指标之间无独立相关性(OR1.30,95%CI:0.94~1.71)。在亚组分析中,高尿酸组中未使用依达拉奉治疗的患者90d时MR S<2的人数多于低尿酸组(OR 2.87,95%CI:1.20~7.16),但使用依达拉奉的高尿酸组与低尿酸组患者之间则无相关性。结论:在急性缺血性卒中患者中,依达拉奉治疗后90d时高尿酸水平与良好预后之间的关系不明显。

Edaravone treatment does not impact outcome of acute ischemic stroke patients with different uric acid levels

Objective:To investigated whether the use of edaravone affected the relationship between uric acid levels and outcome at 90 days in patients with acute ischemic stroke.Methods:Consecutive ischemic stroke patients with modified Rankin Scale(MRS)scores<2 admitted within 24 h were evaluated by retrospective analysis.The patients were divided into low uric acid(≤333μmol/L)group and high uric acid(>333μmol/L)group according to the median uric acid level(333μmol/L)as a cutoff.And,compared the clinical characteristics and favorable outcomes(MRS<2)in the 2 groups at 90 days.The relationship between uric acid levels and 90-day stroke outcome in patients with or without edaravone treatment was further investigated.Results:The high uric acid group had a higher proportion of men,hypertension,atrial fibrillation,and cardioembolic stroke than the low uric acid group.The high uric acid group also had a higher proportion of patients with MRS<2 at 90 days(P=0.013),however,However,there was no independent correlation between uric acid and good outcome indicators in multivariate analysis(OR 1.30,95%CI:0.94–1.71).In subgroup analysis,the high uric acid group without edaravone exhibited a higher proportion of patients with MRS<2 at 90 days than the low uric acid group(OR 2.87,95%CI:1.20–7.16),however,the high uric acid group with edaravone did not exhibit this difference.Conclusion:In acute ischemic stroke,the favorable association between high uric acid levels and outcome at 90 days was not evident in patients treated with edaravone.